Clinical Trial

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2022-12-09; most recent amendment 2026-07-01.
Status change: Not Yet Recruiting → Recruiting 2023-07-26
Trial Details
NCT Number NCT05647265
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma
Enrollment 26 participants
Start Date 2024-11-27
Primary Completion 2026-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-05